Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Ontada®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, has announced a strategic collaboration with Datavant, a health data ...

Janney Montgomery Scott LLC lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 0.3% in the third quarter, according ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Sanofi and the nuclear corporation Orano have agreed to coinvest in a new Orano subsidiary that will develop radioligands based on lead-212 α-emitting isotopes. Sanofi will invest about $325 ...

I want to mention as well that with the new tax laws in France ... specific here or is it a way for Sanofi to maybe be more ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

He also held key positions at Sanofi Oncology, where he oversaw the clinical development of several oncology clinical trials, including a pan-PI3K and mTOR inhibitor. "I am thrilled to join LigaChem ...